Where can I find news about SUNPHARMA.NS?

The latest press releases, SEC filings, and earnings call transcripts for Sun Pharmaceutical Industries Limited (SUNPHARMA.NS) are listed on this page. Press releases come from the company's investor relations feed; filings come directly from SEC EDGAR.

Where are SUNPHARMA.NS's SEC filings?

Sun Pharmaceutical Industries Limited (SUNPHARMA.NS)'s 10-K (annual report), 10-Q (quarterly report), 8-K (current report), and proxy filings are listed in the SEC Filings section on this page with direct links to the official EDGAR copies.

When was SUNPHARMA.NS's last earnings call?

The most recent earnings call transcript for Sun Pharmaceutical Industries Limited (SUNPHARMA.NS) is on this page with the full speaker-by-speaker conversation. Older quarter transcripts are also available — click any past quarter pill to load it.

SUNPHARMA.NS

Sun Pharmaceutical Industries Limited

NSE·Drug Manufacturers, Specialty & Generic · Healthcare

₹1,931.00₹12.00−0.62%

Market cap₹4.63T·Market closed·Jul 23 4:38 AM UTC

Press Releases

Sun Pharma Highlights Advances in Alopecia Areata, Psoriasis, and Acne Research at 2026 AAD Annual Meeting
/PRNewswire/ -- Sun Pharmaceutical Industries Limited (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715 (together with its subsidiaries and/or
prnewswire.comMar 27, 2026 · 10:44 AM
Sun Pharma Announces US FDA Acceptance of Supplemental Biologics License (sBLA) Application for ILUMYA® (tildrakizumab-asmn) for the Treatment of Adults with Active Psoriatic Arthritis
/PRNewswire/ -- Sun Pharmaceutical Industries Limited (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715, "Sun Pharma" and includes its
prnewswire.comMar 16, 2026 · 7:00 AM
Sun Pharma Introduces SUNday, Highlighting the Everyday Realities of Skin Cancer Care
/PRNewswire/ -- Sun Pharmaceutical Industries Limited (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715, "Sun Pharma" and includes its
prnewswire.comFeb 5, 2026 · 8:00 AM
FDA approves label update for UNLOXCYT™ (cosibelimab-ipdl) based on longer-term data that demonstrated improved clinical outcomes in advanced cutaneous squamous cell carcinoma (aCSCC)
As the first and only PD-L1 immune checkpoint inhibitor approved for aCSCC, UNLOXCYT is an evolution in checkpoint inhibition, offering a balance of durable
prnewswire.comNov 25, 2025 · 10:51 PM
Winlevi(R) Receives Regulatory Approval in Brazil - Expanding Global Access to a Breakthrough Acne Treatment
Dublin, Ireland--(Newsfile Corp. - November 14, 2025) - Cosmo Pharmaceuticals N.V. (SIX: COPN), a
feeds.newsfilecorp.comNov 14, 2025 · 1:10 AM

SEC Filings

No recent filings indexed.

Transcripts

PRO

Full call transcripts — prepared remarks + analyst Q&A — with speaker-by-speaker formatting and one-click switching across every quarter on file.

Click below to see what's inside, then upgrade to read every transcript for SUNPHARMA.NS and 80,000+ other tickers.

Transcripts source: company-published earnings calls. Speaker attribution and formatting are processed in-app.

Frequently Asked Questions About SUNPHARMA.NS

Where can I find news about SUNPHARMA.NS?: The latest press releases, SEC filings, and earnings call transcripts for Sun Pharmaceutical Industries Limited (SUNPHARMA.NS) are listed on this page. Press releases come from the company's investor relations feed; filings come directly from SEC EDGAR.
Where are SUNPHARMA.NS's SEC filings?: Sun Pharmaceutical Industries Limited (SUNPHARMA.NS)'s 10-K (annual report), 10-Q (quarterly report), 8-K (current report), and proxy filings are listed in the SEC Filings section on this page with direct links to the official EDGAR copies.
When was SUNPHARMA.NS's last earnings call?: The most recent earnings call transcript for Sun Pharmaceutical Industries Limited (SUNPHARMA.NS) is on this page with the full speaker-by-speaker conversation. Older quarter transcripts are also available — click any past quarter pill to load it.

Sun Pharmaceutical Industries Limited

Frequently Asked Questions About SUNPHARMA.NS

Sun Pharmaceutical Industries Limited

Sun Pharma Highlights Advances in Alopecia Areata, Psoriasis, and Acne Research at 2026 AAD Annual Meeting

Sun Pharma Announces US FDA Acceptance of Supplemental Biologics License (sBLA) Application for ILUMYA® (tildrakizumab-asmn) for the Treatment of Adults with Active Psoriatic Arthritis

Sun Pharma Introduces SUNday, Highlighting the Everyday Realities of Skin Cancer Care

FDA approves label update for UNLOXCYT™ (cosibelimab-ipdl) based on longer-term data that demonstrated improved clinical outcomes in advanced cutaneous squamous cell carcinoma (aCSCC)

Winlevi(R) Receives Regulatory Approval in Brazil - Expanding Global Access to a Breakthrough Acne Treatment

Frequently Asked Questions About SUNPHARMA.NS

Sun Pharma Highlights Advances in Alopecia Areata, Psoriasis, and Acne Research at 2026 AAD Annual Meeting

Sun Pharma Announces US FDA Acceptance of Supplemental Biologics License (sBLA) Application for ILUMYA® (tildrakizumab-asmn) for the Treatment of Adults with Active Psoriatic Arthritis

Sun Pharma Introduces SUNday, Highlighting the Everyday Realities of Skin Cancer Care

FDA approves label update for UNLOXCYT™ (cosibelimab-ipdl) based on longer-term data that demonstrated improved clinical outcomes in advanced cutaneous squamous cell carcinoma (aCSCC)

Winlevi(R) Receives Regulatory Approval in Brazil - Expanding Global Access to a Breakthrough Acne Treatment